Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
49 hedge funds and large institutions have $109M invested in Regulus Therapeutics in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 8 reducing their positions, and 14 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 8
4% less funds holding
Funds holding: 51 → 49 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
19% less capital invested
Capital invested by funds: $134M → $109M (-$25.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.77M |
| 2 |
HM
HealthCor Management
New York
|
+$5.56M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.35M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.05M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$997K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$8.49M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$3.54M |
| 3 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
-$2.21M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.17M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.79M |
RGLS Hedge Fund Activity: Q4 2013 in Review
49 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2013, worth a combined $109M — down 19% from $134M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RGLS and 12 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 22 added.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $5.77M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $8.49M sold.
- 49 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2013, down from 51 in Q3 2013.
- Funds reported $109M of Regulus Therapeutics stock for Q4 2013, down 19% quarter-over-quarter.
- 12 funds opened new Regulus Therapeutics positions in Q4 2013 and 14 closed out, a net change of -2 holders.
- The largest Regulus Therapeutics buyer in Q4 2013 was Wellington Management Group, an estimated $5.77M added.
- The largest Regulus Therapeutics seller in Q4 2013 was Bain Capital Public Equity Management, an estimated $8.49M sold.
Based on aggregated 13F filings for Q4 2013.